ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0303 • ACR Convergence 2024

    Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

    Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

    Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
  • Abstract Number: 0525 • ACR Convergence 2024

    Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

    Varun Dhir1, Harshith Sai Koneti2, Aman Sharma3, sanjay jain4 and shankar naidu5, 1PGIMER, CHD, INDIA, CHANDIGARH, India, 2PGIMER, Chandigarh, Sangareddy, Telangana, India, 3PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 4PGIMER, Chandigarh, Chandigarh, India, 5PGIMER, Chandigarh, India, Chandigarh, India

    Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
  • Abstract Number: 0506 • ACR Convergence 2024

    24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report

    Takao Fujii1, Nami Okamoto2, Asami Abe3, Michiaki Takagi4, Nobunori Takahashi5, Atsuo Nakajima6, Ayako Nakajima7, Shingo Nakayamada8, Keiichiro Nishida9, Takeshi Kawaberi10, Naomi Sunaga10, Yuki Tsujita11, Sumi Chonan12, Masataka Kuwana13 and Yoshiya Tanaka14, 1Wakayama Medical University, Wakayama, Japan, 2Osaka Rosai Hospital, Sakai-city, Osaka, Japan, 3Niigata Rheumatic Center, Shibata, Japan, 4Yamagata University Faculty of Medicine, Yamagata, Japan, 5Nagoya University Graduate School of Medicine, Nagoya, Japan, 6Ueno Dialysis Clinic, Tokyo, Japan, 7Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, 8The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, 9Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 10Abbvie GK, Minato-Ku, Tokyo, Japan, 11AbbVie, Minato City Tokyo, Japan, 12Abbvie GK, Tokyo, Japan, 13Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 14Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
  • Abstract Number: 0551 • ACR Convergence 2024

    Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study

    Dafne Capelusnik1, Anna Molto2, Clementina López Medina3, Desiree van der Heijde4, Robert Landewé5, Maxime Dougados6, Joachim Sieper7 and Sofia Ramiro8, 1Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 2Groupe Hospitalier Cochin, AP-HP, Paris, France, 3Reina Sofia University Hospital, Cordoba, Spain, 4Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 5Amsterdam University Medical Center, Meerssen, Netherlands, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Charité University Medicine Berlin, Berlin, Germany, 8Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
  • Abstract Number: 0542 • ACR Convergence 2024

    Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study

    Clementina López Medina1, Sofia Ramiro2, Dafne Capelusnik3 and Anna Molto4, 1Reina Sofia University Hospital, Cordoba, Spain, 2Leiden University Medical Center, Bunde, Netherlands, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Groupe Hospitalier Cochin, AP-HP, Paris, France

    Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
  • Abstract Number: 0431 • ACR Convergence 2024

    Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors

    Abraham Yair Lujano-Negrete1, Lorena Perez-Barbosa2, Conrado Garcia3, CASSANDRA SKINNER TAYLOR4, Jose Hernandez Linas3, Adriana Lobato-Belmonte3, Yesenia Ambriz Murillo5, Alfonso Gastelum-Strozzi6, Amaranta Manrique de Lara7, Ana Rodriguez-Flores8, Jesus Cardenas-de la Garza9, Marco Maradiaga-Cecena10, Galilea Rodriguez Orozco11, Anahí Carrazco Chapa11, Dionicio Galarza-Delgado12 and Ingris del Pilar Pelaez Ballestas3, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, 1Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, 2Hospital Universitario, UANL, Monterrey, Mexico, 3Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, 4HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, 5Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, 6Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, 7Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, 8Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 9Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 10Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, 11Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, 12UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
  • Abstract Number: 0063 • ACR Convergence 2024

    Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils

    Rayan Najjar1, Noga Rogel2 and Tomas Mustelin3, 1University of Washington, Seattle, 2University of Washinton, Seattle, 3University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
  • Abstract Number: 0470 • ACR Convergence 2024

    New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers

    Veronica Pulito-Cueto1, Belén Atienza-Mateo2, gonzalo Ocejo-Viñals3, Victor M. Mora-Cuesta4, David Iturbe-Fernández4, Joao Carlos Batista-Liz1, María Sebastián Mora-Gil5, Mónica Renuncio-García6, Elena González López3, José M. Cifrián7, Ricardo Blanco-Alonso8 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 4Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, 5Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, 6Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
  • Abstract Number: 0548 • ACR Convergence 2024

    Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis

    David Kiefer1, Juergen Braun2, Uta Kiltz3, Niklas Kolle1, Lucia Schneider1, Ioana Andreica4, Bjoern Buehring5, Philipp Sewerin6, Imke Redeker7, Styliani Tsiami8, Susanne Herbold9 and Xenofon Baraliakos8, 1Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 5Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, 6Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ruhr Universität Bochum, Bochum, Germany, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Herne, Germany

    Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
  • Abstract Number: 0552 • ACR Convergence 2024

    Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study

    Andre Ramon1, Philippe Saas2, Charline Vauchy3, Maxime Samson2 and ERIC TOUSSIROT4, 1Dijon University Hospital, Besançon, France, 2Franche-Comté University, EFS, INSERM, UMR RIGHT, Besançon, France, Besançon, France, 3INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, 4university hospital of BESANCON, besancon, France

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate immune T cells that are located at the mucosal barriers. They play a role in mucosal defense,…
  • Abstract Number: 0325 • ACR Convergence 2024

    The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, Jerapas Thongpiya1, Pojsakorn Danpanichkul1 and Yanint Raksadawan3, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock, TX, 3Weiss Memorial Hospital, Chicago, IL

    Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
  • Abstract Number: 0376 • ACR Convergence 2024

    Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry

    Gaelle Chedeville1, Heinrike Schmeling2, Jean-Philippe Proulx-Gauthier3, Michelle Batthish4, Jean Jacques De Bruycker5, Brian Feldman6, Roberta A Berard7, Roxana Bolaria8, Amieleena Chhabra9, Lily Lim10, Adam Huber11, Matthew Berkowitz12, Thomas Loughin12 and Jaime Guzman13, and CAPRI Registry Investigators, 1The Montreal Children's Hospital, Montreal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3CHU de Quebec - Universite Laval, Quebec, QC, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada, 5UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 7London Health Sciences Centre, London, ON, Canada, 8Victoria Arthritis Center, Victoria, BC, Canada, 9University of British Columbia, Penticton, BC, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11IWK Health Centre, Halifax, NS, Canada, 12Simon Fraser University, Burnaby, BC, Canada, 13University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
  • Abstract Number: 0555 • ACR Convergence 2024

    The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis

    Sinead Maguire1, Nigil Haroon2, Robert Inman3, Melanie Anderson4, Evelyne Gendron5 and Sindhu R. Johnson6, 1University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, Canada, 2Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Quebec City, QC, Canada, 6University of Toronto, Toronto, Canada

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory disease characterized by the involvement of the axial skeleton. Alcohol consumption (AC) is a modifiable lifestyle…
  • Abstract Number: 0563 • ACR Convergence 2024

    Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort

    Manouk de hOoge1, Pedro M. Machado2, Sytske Anne Bergstra3, Maxime Dougados4, Clementina López Medina5, Victoria Navarro Compán6, Diego Benavent7, Denis Poddubnyy8, Levent kilic9, Philippe Carron10, Dirk Elewaut11, Filip Van den Bosch12 and Gaelle Varkas12, 1Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3LUMC, Leiden, Netherlands, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Reina Sofia University Hospital, Cordoba, Spain, 6La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 7Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 8Charite-Universitatsmedizin Berlin, Berlin, Germany, 9Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 10UZ Gent, Gent, Belgium, 11Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 12Ghent University Hospital, Ghent, Belgium

    Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
  • Abstract Number: 0473 • ACR Convergence 2024

    Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology

    NATALUCCI Francesco1, SOKOLOVA Tatiana2, NZEUSSEU TOUKAP Adrien3, GALANT Christine4, ABOUBAKAR Frank5, BAURAIN Jean-François6, CORNELIS Frank6, BORBATH Yvan7, DUREZ Patrick2 and MERIC de BELLEFON Laurent2, 1Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 4Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 5Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, 6Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, 7Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium

    Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…
  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology